

# **BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review**

<https://marketpublishers.com/r/BFD9E29096FEN.html>

Date: May 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: BFD9E29096FEN

## **Abstracts**

BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

BioInvent International AB (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, an inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. The company has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.

### BioInvent International AB Key Recent Developments

Apr 28,2021: BioInvent International: Interim report January-March 2021

Mar 23,2021: Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021

Feb 23,2021: BioInvent International financial statement January 1 - December 31, 2020

Jan 18,2021: An van Es Johansson resigns as board director in BioInvent International

Dec 23,2020: BioInvent receives \$3 million payment related to selection of antibodies under collaboration with Pfizer Inc.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

BioInvent International AB - Key Facts  
BioInvent International AB - Key Employees  
BioInvent International AB - Key Employee Biographies  
BioInvent International AB - Major Products and Services  
BioInvent International AB - History  
BioInvent International AB - Company Statement  
BioInvent International AB - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
BioInvent International AB - Business Description  
Product Category: Revenues from Collaboration Agreements  
Performance  
Product Category: Revenues from External Development Projects  
Performance  
Product Category: Revenues from Technology Licenses  
Performance  
Geographical Segment: Europe  
Performance  
Geographical Segment: Other Countries  
Performance  
Geographical Segment: Sweden  
Performance  
Geographical Segment: USA  
Performance  
R&D Overview  
BioInvent International AB - Corporate Strategy  
BioInvent International AB - SWOT Analysis  
SWOT Analysis - Overview  
BioInvent International AB - Strengths  
BioInvent International AB - Weaknesses  
BioInvent International AB - Opportunities

BioInvent International AB - Threats  
BioInvent International AB - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
BioInvent International AB, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Apr 28, 2021: BioInvent International: Interim report January-March 2021  
Mar 23, 2021: Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021  
Feb 23, 2021: BioInvent International financial statement January 1 - December 31, 2020  
Jan 18, 2021: An van Es Johansson resigns as board director in BioInvent International  
Dec 23, 2020: BioInvent receives \$3 million payment related to selection of antibodies under collaboration with Pfizer Inc.  
Nov 27, 2020: BioInvent strengthens investor relations  
Oct 29, 2020: BioInvent interim report January 1 - September 30, 2020  
Aug 27, 2020: BioInvent Interim report January 1 - June 30, 2020  
Jun 22, 2020: BioInvent presents proof-of-concept data for two TNFR2-targeting antibodies  
May 15, 2020: BioInvent expands anti-TNFR2 program by selecting second monoclonal antibody for further development

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

BioInvent International AB, Key Facts  
BioInvent International AB, Key Employees  
BioInvent International AB, Key Employee Biographies  
BioInvent International AB, Major Products and Services  
BioInvent International AB, History  
BioInvent International AB, Subsidiaries  
BioInvent International AB, Key Competitors  
BioInvent International AB, Ratios based on current share price  
BioInvent International AB, Annual Ratios  
BioInvent International AB, Annual Ratios (Cont...1)  
BioInvent International AB, Interim Ratios  
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
BioInvent International AB, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

BioInvent International AB, Performance Chart (2016 - 2020)

BioInvent International AB, Ratio Charts

BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

BioInvent International AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/BFD9E29096FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BFD9E29096FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970